-
Je něco špatně v tomto záznamu ?
Prothrombotic markers in asymptomatic dyslipidemic subjects
D. Karasek, H. Vaverkova, M. Halenka, D. Jackuliakova, Z. Frysak, L. Slavik, D. Novotny
Jazyk angličtina Země Nizozemsko
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem
Grantová podpora
NS10284
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
ProQuest Central
od 1998-06-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1998-06-01 do Před 1 rokem
- MeSH
- ateroskleróza krev MeSH
- biologické markery krev MeSH
- dospělí MeSH
- dyslipidemie krev MeSH
- koagulační faktory analýza metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipidy krev MeSH
- rizikové faktory MeSH
- senioři MeSH
- sexuální faktory MeSH
- trombóza krev MeSH
- věkové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
The aim of this study was to evaluate the plasma levels of prothrombotic markers--von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA)--in asymptomatic subjects with dyslipidemia. Asymptomatic subjects with dyslipidemia and their relatives (n = 234) were assessed for lipids and prothrombotic markers. Individuals were divided into four dyslipidemic phenotypes (DLP) according to apolipoprotein B (apoB) and triglycerides (TG): DLP1 (n = 58, apoB < 1.2 g/l and TG < 1.5 mmol/l), DLP2 (n = 47, apoB < 1.2 g/l and TG ≥ 1.5 mmol/l), DLP3 (n = 31, apoB ≥ 1.2 g/l and TG < 1.5 mmol/l) and DLP4 (n = 98, apoB ≥ 1.2 g/l and TG ≥ 1.5 mmol/l). Associations between prothrombotic markers and risk factors for atherosclerosis, markers of insulin resistance, and the intima-media thickness of the common carotid artery (IMT) were assessed too. Significant differences in PAI-1 between normolipidemic phenotype--DLP1 (62.5 (35.9-82.9) ng/ml) and hypertriglyceridemic phenotypes--DLP2 (82.2 (61.1-122.1) ng/ml, p < 0.01) and DLP4 (91.4 (63.5-111.8) ng/ml, p < 0.001) after adjustment for age, sex and body mass index, were found. Levels of t-PA were different only between DLP1 and DLP4 (1.9 (0.9-3.3) ng/ml vs. 5.3 (2.5-8.6) ng/ml, p < 0.05). There were no significant differences of vWF between DLPs. PAI-1 and t-PA correlated with lipid parameters, markers of insulin resistance, blood pressure and obesity. VWF was independently associated with IMT, which was increased in DLP4. Individuals with hypertriglyceridemic phenotypes showed increased levels of PAI-1 in comparison with normolipidemic subjects. The elevation of t-PA was presented only in patients with simultaneously elevated TG and apoB. The significant increase of IMT confirmed in the patients with DLP4 reveals individuals with the highest risk for atherosclerosis manifestation.
3rd Department of Internal Medicine University Hospital IP Pavlova 6 77520 Olomouc Czech Republic
3rd Department of Internal Medicine University Hospital Olomouc Czech Republic
Department of Biochemistry University Hospital Olomouc Czech Republic
Department of Hematooncology University Hospital Olomouc Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027394
- 003
- CZ-PrNML
- 005
- 20160226161837.0
- 007
- ta
- 008
- 120816s2011 ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11239-010-0474-4 $2 doi
- 035 __
- $a (PubMed)20640487
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Karásek, David $u 3rd Department of Internal Medicine, University Hospital, IP Pavlova 6, 77520 Olomouc, Czech Republic. david.karasek@fnol.cz $7 stk2007415300
- 245 10
- $a Prothrombotic markers in asymptomatic dyslipidemic subjects / $c D. Karasek, H. Vaverkova, M. Halenka, D. Jackuliakova, Z. Frysak, L. Slavik, D. Novotny
- 520 9_
- $a The aim of this study was to evaluate the plasma levels of prothrombotic markers--von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA)--in asymptomatic subjects with dyslipidemia. Asymptomatic subjects with dyslipidemia and their relatives (n = 234) were assessed for lipids and prothrombotic markers. Individuals were divided into four dyslipidemic phenotypes (DLP) according to apolipoprotein B (apoB) and triglycerides (TG): DLP1 (n = 58, apoB < 1.2 g/l and TG < 1.5 mmol/l), DLP2 (n = 47, apoB < 1.2 g/l and TG ≥ 1.5 mmol/l), DLP3 (n = 31, apoB ≥ 1.2 g/l and TG < 1.5 mmol/l) and DLP4 (n = 98, apoB ≥ 1.2 g/l and TG ≥ 1.5 mmol/l). Associations between prothrombotic markers and risk factors for atherosclerosis, markers of insulin resistance, and the intima-media thickness of the common carotid artery (IMT) were assessed too. Significant differences in PAI-1 between normolipidemic phenotype--DLP1 (62.5 (35.9-82.9) ng/ml) and hypertriglyceridemic phenotypes--DLP2 (82.2 (61.1-122.1) ng/ml, p < 0.01) and DLP4 (91.4 (63.5-111.8) ng/ml, p < 0.001) after adjustment for age, sex and body mass index, were found. Levels of t-PA were different only between DLP1 and DLP4 (1.9 (0.9-3.3) ng/ml vs. 5.3 (2.5-8.6) ng/ml, p < 0.05). There were no significant differences of vWF between DLPs. PAI-1 and t-PA correlated with lipid parameters, markers of insulin resistance, blood pressure and obesity. VWF was independently associated with IMT, which was increased in DLP4. Individuals with hypertriglyceridemic phenotypes showed increased levels of PAI-1 in comparison with normolipidemic subjects. The elevation of t-PA was presented only in patients with simultaneously elevated TG and apoB. The significant increase of IMT confirmed in the patients with DLP4 reveals individuals with the highest risk for atherosclerosis manifestation.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ateroskleróza $x krev $7 D050197
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a koagulační faktory $x analýza $x metabolismus $7 D001779
- 650 _2
- $a dyslipidemie $x krev $7 D050171
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lipidy $x krev $7 D008055
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a sexuální faktory $7 D012737
- 650 _2
- $a trombóza $x krev $7 D013927
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vaverková, Helena, $d 1942- $7 nlk20000083882 $u 3rd Department of Internal Medicine, University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Halenka, Milan $7 xx0047393 $u 3rd Department of Internal Medicine, University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Jackuliaková, Dagmar $7 xx0101837 $u 3rd Department of Internal Medicine, University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Fryšák, Zdeněk $7 xx0082612 $u 3rd Department of Internal Medicine, University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Slavík, Luděk $7 xx0081908 $u Department of Hematooncology, University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Novotný, Dalibor, $d 1965-2015 $7 xx0041926 $u Department of Biochemistry, University Hospital, Olomouc, Czech Republic
- 773 0_
- $w MED00007760 $t Journal of thrombosis and thrombolysis $x 1573-742X $g Roč. 31, č. 1 (2011), s. 27-236
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20640487 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160226161554 $b ABA008
- 999 __
- $a ok $b bmc $g 949436 $s 784740
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 31 $c 1 $d 27-236 $i 1573-742X $m Journal of thrombosis and thrombolysis $n J Thromb Thrombolysis $x MED00007760
- GRA __
- $a NS10284 $p MZ0
- LZP __
- $b NLK112 $a Pubmed-20120816/11/02
